This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-08. Anything still debated is marked as such rather than presented as settled.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
The same phenomenon may happen in conditions that lead to hemolysis, the destruction of red blood cells; in hemolysis, the blood serum is also visibly discolored, while in rhabdomyolysis it is normal. If kidney damage has occurred, microscopy of the urine also reveals urinary casts that appear pigmented and granular.
The scheme might be made far more attractive to the majority of Jews if it held out to them the prospect that when in course of time the Jewish colonists in Palestine grow strong enough to cope with the Arab population they may be allowed to take the management of the internal affairs of Palestine (with the exception of Jerusalem and the holy places) into their own hands. Sykes, having seen the telegram, had discussions with Picot and proposed (making reference to Samuel's memorandum) the creation of an Arab Sultanate under French and British protection, some means of administering the holy places along with the establishment of a company to purchase land for Jewish colonists, who would then become citizens with equal rights to Arabs. Shortly after returning from Petrograd, Sykes briefed Samuel, who then briefed a meeting of Gaster, Weizmann and Sokolow. Gaster recorded in his diary on 16 April 1916: "We are offered French-English condominium in Palest[ine]. Arab Prince to conciliate Arab sentiment and as part of the Constitution a Charter to Zionists for which England would stand guarantee and which would stand by us in every case of friction ... It practically comes to a complete realisation of our Zionist programme.
Cystathionine is an intermediate in the synthesis of cysteine from homocysteine. It is produced by the transsulfuration pathway and is converted into cysteine by cystathionine gamma-lyase (CTH). Biosynthetically, cystathionine is generated from homocysteine and serine by cystathionine beta synthase (upper reaction in the diagram below). It is then cleaved into cysteine and α-ketobutyrate by cystathionine gamma-lyase (lower reaction). An excess of cystathionine in the urine is called cystathioninuria.
Sources: en.wikipedia.org
== Business segments == Bio-Rad's life science products primarily include instruments, software, consumables, reagents, and content for the areas of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. These products are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. Bio-Rad's diagnostic products and systems use a range of technologies and provide clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products are used to support the diagnosis, monitoring, and treatment of diseases and other medical conditions.
Insight into the biosynthesis of the isopropoxy-2-naphthonate appendage was similarly gained by comparative analysis of the ked cluster to those of neocarzinostatin and maduropeptin, enediynes with naphthonate or benzoate substructures, respectively. Five genes, KedN1–N5, bear high sequence homology with the enzymes responsible for naphthonate synthesis in neocarzinostatin—consequently, the intermediacy of 3,6,8-trihydroxy-2-naphthoic acid is proposed in kedarcidin biosynthesis. This compound is believed to be oxygenated to the 3,6,7,8-tetrahydroxy derivative, then triply O-methylated by KedN1, an O-methyltransferase. To furnish the unique isopropoxy substituent, Shen et al. invoke double C-methylation of the corresponding methoxy group by the radical SAM methyltransferase KedN5.
=== Marketing === In July 2026, promotional ice cream trucks themed around American Horror Story: 13 were installed at San Diego Comic-Con. On August 12, 2026, Vogue published the first production stills. The first trailer was released the following day. The second trailer was released on September 10, 2026.
Sources: en.wikipedia.org
=== Hoffman Instrumentation Supply Inc === In 2019, Hoffman Instrumentation Supply Inc was a component vendor to Edwards' US, subsidiary Edwards Vacuum LLC, and held talks about becoming exclusive supplier for some items. It was also proposed that Hoffman would construct subassemblies and complete systems, but only for Edwards. One of Hoffman's key customers enquired whether it could provide a vacuum system that would work with pumps other than Edwards'. Hoffman informed Edwards whose response was to suggest purchasing Hoffman. Information was provided about Hoffman to Edwards for due diligence, under a non disclosure agreement, in order to progress the acquisition. It included technical specifications for the pump agnostic vacuum system and Hoffman's cost structures. The parties did not agree terms to purchase Hoffman and Edwards withdrew from the process. A group of employees left Edwards to work for Hoffman and in 2020, Edwards sought an injunction against Hoffman to prevent misuse of the ex employees's trade secrets. Hoffman counter claimed Edwards used the confidential due diligence information to pitch their products to Hoffman's key customer at prices just below Hoffman's own intended level, and to demand cost reductions from suppliers to match those obtained by Hoffman.
VHF omnidirectional range (VOR) – a worldwide aircraft radio navigation system consisting of fixed ground radio beacons transmitting between 108.00 and 117.95 MHz in the very high frequency (VHF) band. An automated navigational instrument on the aircraft displays a bearing to a nearby VOR transmitter. A VOR beacon transmits two signals simultaneously on different frequencies. A directional antenna transmits a beam of radio waves that rotates like a lighthouse at a fixed rate, 30 times per second. When the directional beam is facing north, an omnidirectional antenna transmits a pulse. By measuring the difference in phase of these two signals, an aircraft can determine its bearing (or "radial") from the station accurately. By taking a bearing on two VOR beacons an aircraft can determine its position (called a "fix") to an accuracy of about 90 metres (300 ft). Most VOR beacons also have a distance measuring capability, called distance measuring equipment (DME); these are called VOR/DME's. The aircraft transmits a radio signal to the VOR/DME beacon and a transponder transmits a return signal. From the propagation delay between the transmitted and received signal the aircraft can calculate its distance from the beacon. This allows an aircraft to determine its location "fix" from only one VOR beacon. Since line-of-sight VHF frequencies are used VOR beacons have a range of about 200 miles for aircraft at cruising altitude. TACAN is a similar military radio beacon system which transmits in 962–1213 MHz, and a combined VOR and TACAN beacon is called a VORTAC.
== Breathing apparatus == The definitive equipment for surface-supplied diving is the breathing apparatus which is supplied with primary breathing gas from the surface via a hose, which is usually part of a diver's umbilical connecting the surface supply systems with the diver, sometimes directly, otherwise via a bell umbilical and bell panel.
=== Quantitative analysis of mixtures === FD-MS can also be used for quantitative analysis when the method of internal standard is applied. There are two common modes of adding an internal standard: either addition of a homologous compound of known weight to the sample, or addition of an isotopically substituted compound of known weight to it. Many earlier applications of FD to analysis of polar and nonvolatile analytes such as polymers and biological molecules have largely been supplanted by newer ionization techniques. However, FD remains one of the only ionization techniques that can produce simple mass spectra with molecular information from hydrocarbons and other particular analytes. The most commonly encountered application of FD at the present time is the analysis of complex mixtures of hydrocarbons such as that found in petroleum fractions.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.